# US 8,277,797 B2 · Interferon-β production modulating Listeria strains and methods for using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,797 B2
- Document ID: US8277797B2
- Status: Granted
- Kind: B2
- Application number: 12/514,787
- Filed: 2007-11-21
- Published: 2010-11-11
- Granted: 2012-10-02
- Earliest claimed: 2006-11-22
- Assignees: The Regents of the University of California
- Inventors: Daniel A. Portnoy; Anat A. Herskovits; Gregory Crimmins
- Web page: https://patentgrep.com/patent/US8277797B2

## CPC

- A61K 39/0208: {Specific bacteria not otherwise provided for}
- A61K 39/02: Bacterial antigens
- A61P 17/00: Drugs for dermatological disorders
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/52: {Bacterial cells; Fungal cells; Protozoal cells}
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/585: {wherein the target is cancer}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Mutant Listeria bacteria that modulate interferon-β production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a TetR gene, a LadR gene, a VirR gene, a MarR gene a MdrL gene, a MdrT gene and a MdrM gene. The subject bacteria find use in a variety of applications, where representative applications of interest include, but are not limited to: (a) use of the subject bacteria as adjuvants; (b) use of the subject bacteria as delivery vectors for introducing macromolecules into a cell; (c) use of the subject bacteria as vaccines for eliciting or boosting a cellular immune response; etc.

## Claims

### Claim 1

A Listeria bacterium comprising a mutation which modulates the expression of a multidrug resistance transporter gene selected from MdrT and MdrM, wherein said Listeria bacterium modulates interferon-β production in macrophages, wherein when said mutation is a mutation in a transcription regulator gene, the mutation is a mutation in the TetR or MarR gene.

### Claim 2 (depends on 1)

The Listeria bacterium according to claim 1, wherein said mutation is a mutation in a transcription regulator gene.

### Claim 3 (depends on 1)

The Listeria bacterium according to claim 1, wherein said mutation is a mutation in a multidrug resistance transporter gene.

### Claim 4 (depends on 2)

The Listeria bacterium according to claim 2, wherein said transcription regulator gene encodes a product that regulates a multi-drug resistance transporter.

### Claim 5 (depends on 3)

The Listeria bacterium according to claim 3, wherein said multidrug resistance transporter gene encodes a product that activates interferon-β production.

### Claim 6 (depends on 1)

The Listeria bacterium according to claim 1, wherein said mutation is chosen from an insertion and a deletion mutation.

### Claim 7 (depends on 1)

The Listeria bacterium according to claim 1, wherein said Listeria bacterium is Listeria monocytogenes.

### Claim 8 (depends on 1)

The Listeria bacterium according to claim 1, wherein said Listeria bacterium is attenuated.

### Claim 9 (depends on 1)

The Listeria bacterium according to claim 1, wherein said Listeria bacterium increases interferon-β production in macrophages as compared to a wild type Listeria bacterium.

### Claim 10 (depends on 1)

The Listeria bacterium according to claim 1, wherein said Listeria bacterium decreases interferon-β production in macrophages as compared to a wild type Listeria bacterium.

### Claim 11 (depends on 9)

The Listeria bacterium according to claim 9, wherein said increase in interferon-β production is Toll-like receptor independent.

### Claim 12 (depends on 9)

The Listeria bacterium according to claim 9, wherein said increase in interferon-β production is IRF-3 dependent.

### Claim 13 (depends on 9)

The Listeria bacterium according to claim 9, wherein said increase in interferon-β production does not induce macrophage cell death.

### Claim 14 (depends on 1)

The Listeria bacterium according to claim 1, wherein said bacterium comprises a heterologous nucleic acid.

### Claim 15 (depends on 14)

The Listeria bacterium according to claim 14, wherein said heterologous nucleic acid is integrated.

### Claim 16 (depends on 14)

The Listeria bacterium according to claim 14, wherein said heterologous nucleic acid encodes at least one product.

### Claim 17 (depends on 16)

The Listeria bacterium according to claim 16, wherein said at least one product is an antigen.

### Claim 18

A Listeria bacterium comprising a mutation which modulates the expression of a multidrug resistance transporter, wherein said Listeria bacterium modulates interferon-β production in macrophages, wherein said Listeria bacterium further comprises a mutation in a UvrA gene and/or a UvrB gene.

### Claim 19 (depends on 1)

A vaccine comprising the Listeria bacterium of claim 1.

### Claim 20

A method for modulating interferon-β production in a human subject, comprising:
administering to a human subject an effective amount of an attenuated Listeria bacterium comprising a mutation which modulates the expression of a multidrug resistance transporter, wherein the Listeria bacterium modulates interferon-β production in macrophages,
wherein said administering modulates interferon-β production in the human subject.

### Claim 21 (depends on 20)

The method according to claim 20, wherein said mutation is a mutation in a transcription regulator gene.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the transcription regulator gene is chosen from a TetR gene, a LadR gene, a VirR gene, and a MarR gene.

### Claim 23 (depends on 20)

The method according to claim 20, wherein said mutation is a mutation in a multidrug resistance transporter gene.

### Claim 24 (depends on 23)

The method according to claim 23, wherein said multidrug resistance transporter gene is chosen from a MdrL gene, a MdrT gene and a MdrM gene.

### Claim 25 (depends on 20)

The method according to claim 20, wherein said mutation is chosen from an insertion mutation and a deletion mutation.

### Claim 26 (depends on 20)

The method according to claim 20, wherein said Listeria bacterium further comprises a mutation in a UvrA gene and/or a UvrB gene.

### Claim 27 (depends on 20)

The method according to claim 20, wherein said Listeria bacterium is Listeria monocytogenes.

### Claim 28 (depends on 20)

The method according to claim 20, wherein said administering provides an increase in interferon-β production.

### Claim 29 (depends on 28)

The method according to claim 28, wherein said administering does not induce macrophage cell death.

### Claim 30 (depends on 20)

The method according to claim 20, wherein said administering provides a decrease in interferon-β production.
